CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

被引:93
作者
Abdo, W. Farid
Bloem, Bastiaan R.
Van Geel, Wieneke J.
Esselink, Rianne A. J.
Verbeek, Marcel M.
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Geriatr, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Nijmegen Med Ctr, Lab Pediat & Neurol, NL-6500 HB Nijmegen, Netherlands
关键词
multiple system atrophy; Parkinson's disease; cerebrospinal fluid; neurofilament; tau; diagnostic accuracy;
D O I
10.1016/j.neurobiolaging.2006.03.010
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background: In early disease stages it can be clinically difficult to differentiate idiopathic Parkinson's disease (IPD) from patients with multiple system atrophy predominated by parkinsonism (MSA-P). Methods: In CSF of 31 patients with IPD, 19 patients with MSA-P, we analyzed tau, neurofilament light chain (NFL) and heavy chain (NFHp35) and the noradrenergic metabolite 3-methoxy-4-hydroxyphenylethyleneglycoI (MHPG). Results: CSF levels of NFL, NFHp35, and tau were significantly increased in MSA-P (all p < 0.0001), whereas, MHPG levels were significantly decreased in MSA-P (p < 0.0001). Optimal discriminative cut-off values for the differentiation between MSA-P and IPD were calculated resulting in high sensitivity (76-94%) and specificity (83-97%) levels. Multivariate logistic regression resulted in the combination of NFL and tau as independent contributors in differentiating between MSA-P and IPD. Discussion: Higher CSF levels of axonal biomarkers could reflect advanced axonal degeneration in MSA-P. Differentiating MSA-P from IPD could be accurately possible with CSF analysis of a combination of axonal and neurotransmitter biomarkers. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:742 / 747
页数:6
相关论文
共 22 条
  • [1] Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease
    Abdo, WF
    de Jong, D
    Hendriks, JCM
    Horstink, MWIM
    Kremer, BPH
    Bloem, BR
    Verbeek, MM
    [J]. MOVEMENT DISORDERS, 2004, 19 (05) : 571 - 579
  • [2] Bräutigam C, 1998, CLIN CHEM, V44, P1897
  • [3] A structural scaffolding of intermediate filaments in health and disease
    Fuchs, E
    Cleveland, DW
    [J]. SCIENCE, 1998, 279 (5350) : 514 - 519
  • [4] Alpha-synuclein and neurodegenerative diseases
    Goedert, M
    [J]. NATURE REVIEWS NEUROSCIENCE, 2001, 2 (07) : 492 - 501
  • [5] Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease
    Holmberg, B
    Rosengren, L
    Karlsson, JE
    Johnels, B
    [J]. MOVEMENT DISORDERS, 1998, 13 (01) : 70 - 77
  • [6] ACCURACY OF CLINICAL-DIAGNOSIS OF IDIOPATHIC PARKINSONS-DISEASE - A CLINICOPATHOLOGICAL STUDY OF 100 CASES
    HUGHES, AJ
    DANIEL, SE
    KILFORD, L
    LEES, AJ
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1992, 55 (03) : 181 - 184
  • [7] SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders
    Litvan, I
    Bhatia, KP
    Burn, DJ
    Goetz, CG
    Lang, AE
    McKeith, I
    Quinn, N
    Sethi, KD
    Shults, C
    Wenning, GK
    [J]. MOVEMENT DISORDERS, 2003, 18 (05) : 467 - 486
  • [8] Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
    Lycke, JN
    Karlsson, JE
    Andersen, O
    Rosengren, LE
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) : 402 - 404
  • [9] Mathias CJ, 1994, NEURODEGENER DIS, P743
  • [10] Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients
    Molina, JA
    Benito-León, J
    Jiménez-Jiménez, FJ
    Ortí-Pareja, M
    Berbel, A
    Tallón-Barranco, A
    de Bustos, F
    Hernánz, A
    [J]. NEUROSCIENCE LETTERS, 1997, 238 (03) : 139 - 141